Kerendia 10Mg 28 Tablets

Description

Kerendia 10Mg 28 Tablets

Kerendia (finerenone) is an FDA-approved tablet taken once a day by adults who have heart failure or chronic kidney disease (from type 2 diabetes).  Kerendia is used to slow down kidney damage, and also to reduce the risk of kidney failure, cardiovascular death, heart attack, and being hospitalized for heart failure.

Kerendia is from the class of medicines called mineralocorticoid receptor antagonists.

Chronic kidney disease (CKD) is when your kidneys are not working properly and they work less effectively over time. Having type 2 diabetes increases your chances of having chronic kidney disease. Often, type 2 diabetics do not have any symptoms in the early stages of CKD, and they might not realize they have it until it is advanced, and they may need to have dialysis or a kidney transplant to survive. If you have diabetes, it is important to get your kidneys checked regularly by having a blood and urine test. If you have signs of reduced kidney function or the start of CKD, early treatment can help prevent you from having extra health problems.

When you have CKD, you have health problems from fluid, electrolytes (minerals required for many bodily processes), and waste building up in the body. If you have CKD, you are also at high risk of heart disease.

One of the reasons CKD can get worse in diabetes is due to inflammation and scarring of the kidneys.

How Kerendia is thought to work is:

• There is a receptor in the kidneys, heart, and blood vessel tissues that is called the mineralocorticoid receptor (MR).
• When MR is overactive, it leads to inflammation, tissue damage, and scarring, which is thought to cause kidney disease and cardiovascular disease to become worse.
• Kerendia blocks the MR so that it is not as active, so the MR is less likely to cause as much inflammation and damage to the kidneys, blood vessels, and heart.
• This means Kerendia slows CKD from getting worse and also lowers the risk of cardiovascular death, having a heart attack, or needing to be hospitalized for heart failure.

Kerendia’s mechanism of action is as a non-steroidal mineralocorticoid receptor antagonist (nsMRA) that selectively and potently blocks mineralocorticoid receptor overactivation in the heart and kidneys.